Manufacturers are actively seeking approval from the U.S. Food & Drug Administration (FDA) for new therapies, ensuring a steady flow in the robust drug pipeline.
Notable newcomers in the immunology and oncology space have already received approval this year. At the same time, there are breakthrough and novel treatments across neurology, psychiatry, and pulmonology awaiting approval.
Download the pipeline update summary to see all 10 new therapies.
How Will New Drug Launches Affect Your Pharmacy Benefit?
It’s important to proactively monitor the evolving pipeline to stay on top of new therapies and understand how they may affect your pharmacy benefit coverage and cost management strategies.
It’s also wise to proactively monitor your member population so you’re aware of members newly diagnosed with conditions that may require one of these drugs for treatment. Xevant’s ClinicalLogic tool automates this process for you. With ClinicalLogic, coupled with automatic alerts, you are instantly notified of newly diagnosed members along with changes in utilization patterns of specific drugs.
From there you can make an informed decision on which therapies the plan should prefer on the formulary to best balance cost with member access.
How can Xevant’s real-time reporting tools help you prepare for the launch of new drugs? Ask us.